Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Trauma and Emergency Surgery
Published in: European Journal of Trauma and Emergency Surgery 3/2018

Open Access 01-06-2018 | Review Article

Danger signals in trauma

Authors: Borna Relja, Katharina Mörs, Ingo Marzi

Published in: European Journal of Trauma and Emergency Surgery | Issue 3/2018

Login to get access

Abstract

This review summarizes a short list of currently discussed trauma-induced danger-associated molecular patterns (DAMP). Due to the bivalent character and often pleiotropic effects of a DAMP, it is difficult to describe its “friend or foe” role in post-traumatic inflammation and regeneration, both systemically as well locally in tissues. DAMP can be used as biomarkers to indicate or monitor disease or injury severity, but also may serve as clinically applicable parameters for better indication and timing of surgery. Due to the inflammatory processes at the local tissue level or the systemic level, the precise role of DAMP is not always clear to define. While in vitro and experimental studies allow for the detection of these biomarkers at the different levels of an organism—cellular, tissue, circulation—this is not always easily transferable to the human setting. Increased knowledge exploring the dual role of DAMP after trauma, and concentrating on their nuclear functions, transcriptional targets, release mechanisms, cellular sources, multiple functions, their interactions and potential therapeutic targeting is warranted.
Literature
1.
2.
3.
Wutzler S, et al. Pathophysiology of multiple trauma: intensive care medicine and timing of treatment. Chirurg. 2013;84(9):753–8.PubMedCrossRef
4.
Wafaisade A, et al. Epidemiology and risk factors of sepsis after multiple trauma: an analysis of 29,829 patients from the Trauma Registry of the German Society for Trauma Surgery. Crit Care Med. 2011;39(4):621–8.PubMedCrossRef
5.
Osuka AO, Ueyama H, Shimazu M, Lederer T. JA., Immune response to traumatic injury: harmony and discordance of immune system homeostasis. Acute Medicine Surgery. 2014;1(2):6.CrossRef
6.
Rose S, Marzi I. Mediators in polytrauma: pathophysiological significance and clinical relevance. Langenbecks Arch Surg. 1998;383(3–4):199–208.PubMedCrossRef
7.
Adib-Conquy M, Cavaillon JM. Compensatory anti-inflammatory response syndrome. Thromb Haemost. 2009;101(1):36–47.PubMedCrossRef
8.
Bhan C, et al. Role of cellular events in the pathophysiology of sepsis. Inflamm Res. 2016;65(11):853–68.PubMedCrossRef
9.
10.
11.
Islam MN, Bradley BA, Ceredig R. Sterile post-traumatic immunosuppression. Clin Transl Immunol. 2016;5(4):e77.CrossRef
12.
13.
Tsukamoto T, Chanthaphavong RS, Pape HC. Current theories on the pathophysiology of multiple organ failure after trauma. Injury. 2010;41(1):21–6.PubMedCrossRef
14.
Horst K, et al. Impact of haemorrhagic shock intensity on the dynamic of alarmins release in porcine poly-trauma animal model. Eur J Trauma Emerg Surg. 2016;42(1):67–75.PubMedCrossRef
15.
16.
17.
18.
19.
20.
Lotze MT, et al. The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol Rev. 2007;220:60–81.PubMedCrossRef
21.
Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol. 2007;81(1):1–5.PubMedCrossRef
22.
Manson J, Thiemermann C, Brohi K. Trauma alarmins as activators of damage-induced inflammation. Br J Surg. 2012;99(Suppl 1):12–20.PubMedCrossRef
23.
Zedler S, Faist E. The impact of endogenous triggers on trauma-associated inflammation. Curr Opin Crit Care. 2006;12(6):595–601.PubMedCrossRef
24.
Janeway CA. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol. 1989;54(Pt 1):1–13.PubMedCrossRef
25.
26.
27.
Medzhitov R, Preston-Hurlburt P, Janeway CA. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature. 1997;388(6640):394–7.PubMedCrossRef
28.
29.
Bryant CE, et al. Advances in Toll-like receptor biology: modes of activation by diverse stimuli. Crit Rev Biochem Mol Biol. 2015;50(5):359–79.PubMedCrossRef
30.
Creagh EM, L.A.J., O’Neill. TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity. Trends Immunol. 2006;27(8):352–7.PubMedCrossRef
31.
Gay NJ, et al. A leucine-rich repeat peptide derived from the Drosophila Toll receptor forms extended filaments with a beta-sheet structure. FEBS Lett. 1991;291(1):87–91.PubMedCrossRef
32.
Ibrahim ZA, et al. RAGE and TLRs: relatives, friends or neighbours? Mol Immunol. 2013;56(4):739–44.PubMedCrossRef
33.
34.
Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2001;2(8):675–80.PubMedCrossRef
35.
Takeda K, Akira S. Toll-like receptors. Curr Protoc Immunol. 2015;109:1–10.
36.
Wegiel B, Hauser CJ, Otterbein LE. Heme as a danger molecule in pathogen recognition. Free Radic Biol Med. 2015;89:651–61.PubMedCrossRef
37.
Schwandner R, et al. Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. J Biol Chem. 1999;274(25):17406–9.PubMedCrossRef
38.
Poltorak A, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science. 1998;282(5396):2085–8.PubMedCrossRef
39.
Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity. 2011;34(5):637–50.PubMedCrossRef
40.
41.
42.
43.
Yamamoto M, et al., Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science (New York). 2003;301(5633):640–3.CrossRef
44.
45.
Tang D, et al. Hydrogen peroxide stimulates macrophages and monocytes to actively release HMGB1. J Leukoc Biol. 2007;81(3):741–7.PubMedCrossRef
46.
Bauernfeind F, et al. Inflammasomes: current understanding and open questions. Cell Mol Life Sci. 2011;68(5):765–83.PubMedCrossRef
47.
Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell. 2002;10(2):417–26.PubMedCrossRef
48.
Muruve DA, et al. The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature. 2008;452(7183):103–7.PubMedCrossRef
49.
Agostini L, et al. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity. 2004;20(3):319–25.PubMedCrossRef
50.
Arend WP, Palmer G, Gabay C. IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev. 2008;223:20–38.PubMedCrossRef
51.
Cerretti DP, et al. Molecular cloning of the interleukin-1 beta converting enzyme. Science. 1992;256(5053):97–100.PubMedCrossRef
52.
Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. Nat Rev Immunol. 2013;13(6):397–411.PubMedCrossRef
53.
Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol. 2009;27:229–65.PubMedCrossRef
54.
Proell M, et al. The CARD plays a critical role in ASC foci formation and inflammasome signalling. Biochem J. 2013;449(3):613–21.PubMedCrossRef
55.
Relja B, et al. Nlrp1 inflammasome is downregulated in trauma patients. J Mol Med (Berl). 2015;93(12):1391–400.CrossRef
56.
Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 2009;27(1):519–50.PubMedCrossRef
57.
van de Veerdonk FL, et al. Inflammasome activation and IL-1beta and IL-18 processing during infection. Trends Immunol. 2011;32(3):110–6.PubMedCrossRef
58.
59.
60.
61.
62.
63.
Yang J, Liu Z, Xiao TS. Post-translational regulation of inflammasomes. Cell Mol Immunol. 2017;14(1):65–79.PubMedCrossRef
64.
65.
66.
67.
Yamasaki S, et al. Mincle is an ITAM-coupled activating receptor that senses damaged cells. Nat Immunol. 2008;9(10) :1179–88.PubMedCrossRef
68.
Zhou H, et al. IRAKM-Mincle axis links cell death to inflammation: pathophysiological implications for chronic alcoholic liver disease. Hepatology. 2016;64(6) :1978–93.PubMedCrossRef
69.
Hori O, et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem. 1995;270(43) :25752–61.PubMedCrossRef
70.
Hofmann MA, et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell. 1999;97(7):889–901.PubMedCrossRef
71.
Du Yan S, et al. Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease. Proc Natl Acad Sci USA. 1997;94(10):5296–301.PubMedPubMedCentralCrossRef
72.
Demling N, et al. Promotion of cell adherence and spreading: a novel function of RAGE, the highly selective differentiation marker of human alveolar epithelial type I cells. Cell Tissue Res. 2006;323(3):475–88.PubMedCrossRef
73.
74.
Chen X, et al. RAGE: a potential target for Abeta-mediated cellular perturbation in Alzheimer’s disease. Curr Mol Med. 2007;7(8):735–42.PubMedCrossRef
75.
76.
Sorci G, et al. RAGE in tissue homeostasis, repair and regeneration. Biochim Biophys Acta. 2013;1833(1):101–9.PubMedCrossRef
77.
Kierdorf K, Fritz G. RAGE regulation and signaling in inflammation and beyond. J Leukoc Biol. 2013;94(1):55–68.PubMedCrossRef
78.
79.
Schmidt AM, et al. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest. 2001;108(7):949–55.PubMedPubMedCentralCrossRef
80.
Bierhaus A, et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med (Berl). 2005;83(11):876–86.CrossRef
81.
Wu X, et al. The activation of HMGB1 as a progression factor on inflammation response in normal human bronchial epithelial cells through RAGE/JNK/NF-kappaB pathway. Mol Cell Biochem. 2013;380(1–2):249–57.PubMedCrossRef
82.
Chen L, et al. Overexpression of RAGE contributes to cigarette smoke-induced nitric oxide generation in COPD. Lung. 2014;192(2):267–75.PubMedCrossRef
83.
Bianchi ME, Agresti A. HMG proteins: dynamic players in gene regulation and differentiation. Curr Opin Genet Dev. 2005;15(5):496–506.PubMedCrossRef
84.
Pandolfi F, et al. Key role of DAMP in inflammation, cancer, and tissue repair. Clin Ther. 2016;38(5):1017–28.PubMedCrossRef
85.
86.
Bellussi LM, et al. Are HMGB1 protein expression and secretion markers of upper airways inflammatory diseases? J Biol Regul Homeost Agents. 2013;27(3):791–804.PubMed
87.
Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002;418(6894):191–5.PubMedCrossRef
88.
Cohen MJ, et al. Early release of high mobility group box nuclear protein 1 after severe trauma in humans: role of injury severity and tissue hypoperfusion. Crit Care. 2009;13(6):R174.PubMedPubMedCentralCrossRef
89.
Levy RM, et al. Systemic inflammation and remote organ injury following trauma require HMGB1. Am J Physiol Regul Integr Comp Physiol. 2007;293(4):R1538-44.PubMedCrossRef
90.
Zhang BF, et al. Anti-high mobility group box-1 (HMGB1) antibody attenuates kidney damage following experimental crush injury and the possible role of the tumor necrosis factor-alpha and c-Jun N-terminal kinase pathway. J Orthop Surg Res. 2017;12(1):110.PubMedPubMedCentralCrossRef
91.
Parker TM, et al. The danger zone: systematic review of the role of HMGB1 danger signalling in traumatic brain injury. Brain Inj. 2017;31(1):2–8.PubMedCrossRef
92.
Kim JY, et al. HMGB1 contributes to the development of acute lung injury after hemorrhage. Am J Physiol Lung Cell Mol Physiol. 2005;288(5):L958–65.CrossRef
93.
Ogawa EN, et al. Contribution of high-mobility group box-1 to the development of ventilator-induced lung injury. Am J Respir Crit Care Med. 2006;174(4):400–7.PubMedCrossRef
94.
95.
van Zoelen MA, et al. Pulmonary levels of high-mobility group box 1 during mechanical ventilation and ventilator-associated pneumonia. Shock. 2008;29(4):441–5.PubMedCrossRef
96.
Ueno H, et al. Contributions of high mobility group box protein in experimental and clinical acute lung injury. Am J Respir Crit Care Med. 2004;170(12):1310–6.PubMedCrossRef
97.
98.
Arshad MI, Piquet-Pellorce C, Samson M. IL-33 and HMGB1 alarmins: sensors of cellular death and their involvement in liver pathology. Liver Int. 2012;32(8):1200–10.PubMedCrossRef
99.
Yang H, Tracey KJ. Targeting HMGB1 in inflammation. Biochim Biophys Acta. 2010;1799(1–2):149–56.PubMedCrossRef
100.
101.
Keyel PA. How is inflammation initiated? Individual influences of IL-1, IL-18 and HMGB1. Cytokine. 2014;69(1):136–45.PubMedCrossRef
102.
van Griensven M. Cytokines as biomarkers in polytraumatized patients. Unfallchirurg. 2014;117(8):699–702.PubMedCrossRef
103.
104.
Dinarello CA. A clinical perspective of IL-1beta as the gatekeeper of inflammation. Eur J Immunol. 2011;41(5):1203–17.PubMedCrossRef
105.
Aden N, et al. Epithelial cells promote fibroblast activation via IL-1alpha in systemic sclerosis. J Invest Dermatol. 2010;130(9):2191–200.PubMedCrossRef
106.
Rosenwasser LJ, Dinarello CA, Rosenthal AS. Adherent cell function in murine T-lymphocyte antigen recognition. IV. Enhancement of murine T-cell antigen recognition by human leukocytic pyrogen. J Exp Med. 1979;150(3):709–14.PubMedCrossRef
107.
Lefrancais E, Cayrol C. Mechanisms of IL-33 processing and secretion: differences and similarities between IL-1 family members. Eur Cytokine Netw. 2012;23(4):120–7.PubMed
108.
Maier JA, Statuto M, Ragnotti G. Endogenous interleukin 1 alpha must be transported to the nucleus to exert its activity in human endothelial cells. Mol Cell Biol. 1994;14(3):1845–51.PubMedPubMedCentralCrossRef
109.
Werman A, et al. The precursor form of IL-1alpha is an intracrine proinflammatory activator of transcription. Proc Natl Acad Sci USA. 2004;101(8):2434–9.PubMedPubMedCentralCrossRef
110.
Sakurai T, et al. Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell. 2008;14(2):156–65.PubMedPubMedCentralCrossRef
111.
112.
Kobayashi Y, et al. Identification of calcium-activated neutral protease as a processing enzyme of human interleukin 1 alpha. Proc Natl Acad Sci USA. 1990;87(14):5548–52.PubMedPubMedCentralCrossRef
113.
Kavita U, Mizel SB. Differential sensitivity of interleukin-1 alpha and -beta precursor proteins to cleavage by calpain, a calcium-dependent protease. J Biol Chem. 1995;270(46):27758–65.PubMedCrossRef
114.
Carruth LM, Demczuk S, Mizel SB. Involvement of a calpain-like protease in the processing of the murine interleukin 1 alpha precursor. J Biol Chem. 1991;266(19):12162–7.PubMed
115.
Bertheloot D, Latz E. HMGB1, IL-1alpha, IL-33 and S100 proteins: dual-function alarmins. Cell Mol Immunol. 2017;14(1):43–64.PubMedCrossRef
116.
117.
118.
Jacobs RF, et al. Elevated interleukin-1 release by human alveolar macrophages during the adult respiratory distress syndrome. Am Rev Respir Dis. 1989;140(6):1686–92.PubMedCrossRef
119.
Rider P, et al. The transcription of the alarmin cytokine interleukin-1 alpha is controlled by hypoxia inducible factors 1 and 2 alpha in hypoxic cells. Front Immunol. 2012;3:290.PubMedPubMedCentralCrossRef
120.
Thornton P, et al. Platelet interleukin-1alpha drives cerebrovascular inflammation. Blood. 2010;115(17):3632–9.PubMedCrossRef
121.
Turner NA, et al. Interleukin-1alpha stimulates proinflammatory cytokine expression in human cardiac myofibroblasts. Am J Physiol Heart Circ Physiol. 2009;297(3):H1117-27.PubMedCrossRef
122.
Pichery M, et al. Endogenous IL-33 is highly expressed in mouse epithelial barrier tissues, lymphoid organs, brain, embryos, and inflamed tissues: in situ analysis using a novel Il-33-LacZ gene trap reporter strain. J Immunol. 2012;188(7):3488–95.PubMedCrossRef
123.
Baekkevold ES, et al. Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. Am J Pathol. 2003;163(1):69–79.PubMedPubMedCentralCrossRef
124.
Carriere V, et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci USA. 2007;104(1):282–7.PubMedCrossRef
125.
Hirsiger S, et al., Danger signals activating the immune response after trauma. Mediat Inflamm. 2012;2012:315941.CrossRef
126.
Schmitz J, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23(5):479–90.PubMedCrossRef
127.
Palmer G, et al. The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33. Cytokine. 2008;42(3):358–64.PubMedCrossRef
128.
129.
Lefrancais E, et al. IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G. Proc Natl Acad Sci USA. 2012;109(5):1673–8.PubMedPubMedCentralCrossRef
130.
Roussel L, et al. Molecular mimicry between IL-33 and KSHV for attachment to chromatin through the H2A-H2B acidic pocket. EMBO Rep. 2008;9(10):1006–12.PubMedPubMedCentralCrossRef
131.
Bessa J, et al. Altered subcellular localization of IL-33 leads to non-resolving lethal inflammation. J Autoimmun. 2014;55:33–41.PubMedCrossRef
132.
Cohen ES, et al. Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation. Nat Commun. 2015;6:8327.PubMedCrossRef
133.
Cayrol C, Girard J-P. IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy. Curr Opin Immunol. 2014;31:31–7.PubMedCrossRef
134.
Ali S, et al. IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells. Proc Natl Acad Sci USA. 2007;104(47):18660–5.PubMedPubMedCentralCrossRef
135.
Humphreys NE, et al. IL-33, a potent inducer of adaptive immunity to intestinal nematodes. J Immunol. 2008;180(4):2443–9.PubMedCrossRef
136.
Park JH, et al. Risk factors for sepsis in Korean trauma patients. Eur J Trauma Emerg Surg. 2016;42(4):453–8.PubMedCrossRef
137.
Tranca S, et al. sTREM-1, sIL-2Ralpha, and IL-6, but not sCD163, might predict sepsis in polytrauma patients: a prospective cohort study. Eur J Trauma Emerg Surg. 2017;43(3):363–70.PubMedCrossRef
138.
Lalwani S, et al. Sepsis in fatal pelvic trauma patients: report from a level-1 Indian Trauma Centre. Eur J Trauma Emerg Surg. 2016;42(1):43–5.PubMedCrossRef
139.
Alves-Filho JC, et al. Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection. Nat Med. 2010;16(6):708–12.PubMedCrossRef
140.
Kurowska-Stolarska M, et al. IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J Immunol. 2009;183(10):6469–77.PubMedCrossRef
141.
Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. 2008;359(22):2355–65.PubMedCrossRef
142.
Palmer G, et al. Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum. 2009;60(3):738–49.PubMedCrossRef
143.
Gadani SP, et al. The glia-derived alarmin IL-33 orchestrates the immune response and promotes recovery following CNS injury. Neuron. 2015;85(4):703–9.PubMedCrossRef
144.
Pomeshchik Y, et al. Interleukin-33 treatment reduces secondary injury and improves functional recovery after contusion spinal cord injury. Brain Behav Immun. 2015;44:68–81.PubMedCrossRef
145.
146.
Moore BW. A soluble protein characteristic of the nervous system. Biochem Biophys Res Commun. 1965;19(6):739–44.PubMedCrossRef
147.
Foell D, et al. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leukoc Biol. 2007;81(1):28–37.PubMedCrossRef
148.
Timmermans K, et al. Danger in the intensive care unit: Damps in critically Ill patients. Shock. 2016;45(2):108–16.PubMedCrossRef
149.
Pruenster M, et al. S100A8/A9: from basic science to clinical application. Pharmacol Ther. 2016;167:120–31.PubMedCrossRef
150.
Fontaine M, et al. Innate danger signals in acute injury: from bench to bedside. Anaesth Crit Care Pain Med. 2016;35(4):283–92.PubMedCrossRef
151.
De Lorenzo BH, et al. Macrophage suppression following phagocytosis of apoptotic neutrophils is mediated by the S100A9 calcium-binding protein. Immunobiology. 2010;215(5):341–7.PubMedCrossRef
152.
Ghavami S, et al. S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase-dependent pathway. J Leukoc Biol. 2008;83(6):1484–92.PubMedCrossRef
153.
Loeser RF, et al. Articular chondrocytes express the receptor for advanced glycation end products: potential role in osteoarthritis. Arthritis Rheum. 2005;52(8):2376–85.PubMedPubMedCentralCrossRef
154.
Ellis EF, et al. S100B protein is released from rat neonatal neurons, astrocytes, and microglia by in vitro trauma and anti-S100 increases trauma-induced delayed neuronal injury and negates the protective effect of exogenous S100B on neurons. J Neurochem. 2007;101(6):1463–70.PubMedCrossRef
155.
156.
Oesterle A, Bowman MA. S100A12 and the S100/calgranulins: emerging biomarkers for atherosclerosis and possibly therapeutic targets. Arterioscler Thromb Vasc Biol. 2015;35(12):2496–507.PubMedPubMedCentralCrossRef
157.
Dassan P, Keir G, Brown MM. Criteria for a clinically informative serum biomarker in acute ischaemic stroke: a review of S100B. Cerebrovasc Dis. 2009;27(3):295–302.PubMedCrossRef
158.
Gogas H, et al. Biomarkers in melanoma. Ann Oncol. 2009;20(Suppl 6):vi8–13.CrossRef
159.
Gazzolo D, Michetti F. Perinatal S100B protein assessment in human unconventional biological fluids: a minireview and new perspectives. Cardiovasc Psychiatry Neurol, 2010;2010: 703563.PubMedPubMedCentralCrossRef
160.
Mocellin S, Zavagno G, Nitti D. The prognostic value of serum S100B in patients with cutaneous melanoma: a meta-analysis. Int J Cancer. 2008;123(10):2370–6.PubMedCrossRef
161.
Payen D, et al. Gene profiling in human blood leucocytes during recovery from septic shock. Intensive Care Med. 2008;34(8):1371–6.PubMedCrossRef
162.
Zhang LN, et al. Diagnostic and predictive levels of calcium-binding protein A8 and tumor necrosis factor receptor-associated factor 6 in sepsis-associated encephalopathy: a prospective observational study. Chin Med J (Engl). 2016;129(14):1674–81.CrossRef
163.
Uhel F, et al. Early expansion of circulating granulocytic myeloid-derived suppressor cells predicts development of nosocomial infections in patients with sepsis. Am J Respir Crit Care Med. 2017;196(3):315–27.PubMedCrossRef
164.
Azmitia EC. Cajal’s hypotheses on neurobiones and neurotropic factor match properties of microtubules and S-100 beta. Prog Brain Res. 2002;136:87–100.PubMedCrossRef
165.
Van Eldik LJ, Wainwright MS. The Janus face of glial-derived S100B: beneficial and detrimental functions in the brain. Restor Neurol Neurosci. 2003;21(3–4):97–108.PubMed
166.
Thelin EP, et al. Assessing bicycle-related trauma using the biomarker S100B reveals a correlation with total injury severity. Eur J Trauma Emerg Surg. 2016;42(5):617–25.PubMedCrossRef
167.
168.
Goyal A, et al. S100b as a prognostic biomarker in outcome prediction for patients with severe traumatic brain injury. J Neurotrauma. 2013;30(11):946–57.PubMedPubMedCentralCrossRef
169.
Kellermann I, et al. Early CSF and serum S100B concentrations for outcome prediction in traumatic brain injury and subarachnoid hemorrhage. Clin Neurol Neurosurg. 2016;145:79–83.PubMedCrossRef
170.
171.
Chernov AV, et al. The calcium-binding proteins S100A8 and S100A9 initiate the early inflammatory program in injured peripheral nerves. J Biol Chem. 2015;290(18):11771–84.PubMedPubMedCentralCrossRef
172.
Dang X, et al. S100B ranks as a new marker of multiple traumas in patients and may accelerate its development by regulating endothelial cell dysfunction. Int J Clin Exp Pathol. 2014;7(7):3818–26.PubMedPubMedCentral
173.
Anderson RE, et al. High serum S100B levels for trauma patients without head injuries. Neurosurgery. 2001;48(6):1255–8; Discussion 1258–60.PubMed
174.
Pfortmueller CA, et al. S-100 B concentrations are a predictor of decreased survival in patients with major trauma, independently of head injury. PLoS ONE. 2016;11(3):e0152822.PubMedPubMedCentralCrossRef
175.
176.
177.
Pisetsky DS. Immune activation by histones: plusses and minuses in inflammation. Eur J Immunol. 2013;43(12):3163–6.PubMedCrossRef
178.
Huang H, et al. Endogenous histones function as alarmins in sterile inflammatory liver injury through Toll-like receptor 9 in mice. Hepatology. 2011;54(3):999–1008.PubMedCrossRef
179.
180.
181.
182.
Semeraro F, et al. Extracellular histones promote thrombin generation through platelet-dependent mechanisms: involvement of platelet TLR2 and TLR4. Blood. 2011;118(7):1952–61.PubMedPubMedCentralCrossRef
183.
Kawai C, et al. Circulating extracellular histones are clinically relevant mediators of multiple organ injury. Am J Pathol. 2016;186(4):829–43.PubMedCrossRef
184.
185.
186.
Schopf FH, Biebl MM, Buchner J. The HSP90 chaperone machinery. Nat Rev Mol Cell Biol. 2017;18(6):345–60.PubMedCrossRef
187.
188.
Arnold-Schild D, et al. Cutting edge: receptor-mediated endocytosis of heat shock proteins by professional antigen-presenting cells. J Immunol. 1999;162(7):3757–60.PubMed
189.
190.
Tang D, et al. The anti-inflammatory effects of heat shock protein 72 involve inhibition of high-mobility-group box 1 release and proinflammatory function in macrophages. J Immunol. 2007;179(2):1236–44.PubMedCrossRef
191.
192.
Giffard RG, Yenari MA. Many mechanisms for HSP70 protection from cerebral ischemia. J Neurosurg Anesthesiol. 2004;16(1):53–61.PubMedCrossRef
193.
Adachi H, et al. Heat shock proteins in neurodegenerative diseases: pathogenic roles and therapeutic implications. Int J Hyperth. 2009;25(8):647–54.CrossRef
194.
Wheeler DS, et al. Extracellular heat shock protein 60 (HSP60) levels in children with septic shock. Inflamm Res. 2007;56(5):216–9.PubMedCrossRef
195.
Wheeler DS, et al. Extracellular HSP70 levels in children with septic shock. Pediatr Crit Care Med. 2005;6(3):308–11.PubMedCrossRef
196.
Hashiguchi N, et al. Enhanced expression of heat shock proteins in activated polymorphonuclear leukocytes in patients with sepsis. J Trauma. 2001;51(6):1104–9.PubMed
197.
Chatterjee A, et al. Heat shock protein 90 inhibitors prolong survival, attenuate inflammation, and reduce lung injury in murine sepsis. Am J Respir Crit Care Med. 2007;176(7):667–75.PubMedPubMedCentralCrossRef
198.
Singleton KD, Wischmeyer PE. Effects of HSP70.1/3 gene knockout on acute respiratory distress syndrome and the inflammatory response following sepsis. Am J Physiol Lung Cell Mol Physiol. 2006;290(5):L956-61.PubMedCrossRef
199.
McConnell KW, et al. The role of heat shock protein 70 in mediating age-dependent mortality in sepsis. J Immunol. 2011;186(6):3718–25.PubMedCrossRef
200.
Hashiguchi N, et al. Enhanced expression of heat shock proteins in leukocytes from trauma patients. J Trauma. 2001;50(1):102–7.PubMedCrossRef
201.
Ogura H, et al. Long-term enhanced expression of heat shock proteins and decelerated apoptosis in polymorphonuclear leukocytes from major burn patients. J Burn Care Rehabil. 2002;23(2):103–9.PubMedCrossRef
202.
Pespeni M, et al. Serum levels of HSP60 correlate with the development of acute lung injury after trauma. J Surg Res. 2005;126(1):41–7.PubMedCrossRef
203.
Ren B, et al. Serum levels of HSP70 and other DAMP proteins can aid in patient diagnosis after traumatic injury. Cell Stress Chaperones. 2016;21(4):677–86.PubMedPubMedCentralCrossRef
204.
205.
Pittet JF, et al. Serum levels of HSP72 measured early after trauma correlate with survival. J Trauma. 2002;52(4):611–7; Discussion 617.PubMed
206.
Preissner KT, Herwald H. Extracellular nucleic acids in immunity and cardiovascular responses: between alert and disease. Thromb Haemost. 2017;117(7):1272–82.PubMedCrossRef
207.
Zhang Q, Raoof M, Chen Y, Sumi Y, Sursal T, Junger W, Brohi K, Itagaki K, Hauser CJ. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature. 2010;464(7285):104–7.PubMedPubMedCentralCrossRef
208.
Roers A, Hiller B, Hornung V. Recognition of endogenous nucleic acids by the innate immune system. Immunity. 2016;44(4):739–54.PubMedCrossRef
209.
210.
Ahmed AI, Soliman RA, Samir S. Cell free DNA and procalcitonin as early markers of complications in ICU patients with multiple trauma and major surgery. Clin Lab. 2016;62(12):2395–404.PubMed
211.
Willart MA, Lambrecht BN. The danger within: endogenous danger signals, atopy and asthma. Clin Exp Allergy. 2009;39(1):12–9.PubMedCrossRef
212.
Novak I. ATP as a signaling molecule: the exocrine focus. News Physiol Sci. 2003;18:12–7.PubMed
213.
214.
215.
Chen Y, et al. ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors. Science. 2006;314(5806):1792–5.PubMedCrossRef
216.
Mendonca R, Silveira AA, Conran N. Red cell DAMPs and inflammation. Inflamm Res. 2016;65(9):665–78.PubMedCrossRef
217.
Schaer DJ, et al. Haptoglobin, hemopexin, and related defense pathways-basic science, clinical perspectives, and drug development. Front Physiol. 2014;5:415.PubMedPubMedCentralCrossRef
218.
219.
Dear JW, et al. Cyclophilin A is a damage-associated molecular pattern molecule that mediates acetaminophen-induced liver injury. J Immunol. 2011;187(6):3347–52.PubMedCrossRef
220.
Tegeder I, et al. Elevated serum cyclophilin levels in patients with severe sepsis. J Clin Immunol. 1997;17(5):380–6.PubMedCrossRef
221.
Arun P, et al., Extracellular cyclophilin A protects against blast-induced neuronal injury. Neurosci Res. 2013;76(1–2):98–100.PubMedCrossRef
222.
Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature. 2003;425(6957):516–21.PubMedCrossRef
223.
224.
Martinon F, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440(7081):237–41.PubMedCrossRef
225.
Liang J, et al. Elevated serum uric acid after injury correlates with the early acute kidney in severe burns. Burns. 2015;41(8):1724–31.PubMedCrossRef
Metadata
Title
Danger signals in trauma
Authors
Borna Relja
Katharina Mörs
Ingo Marzi
Publication date
01-06-2018
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Trauma and Emergency Surgery / Issue 3/2018
Print ISSN: 1863-9933
Electronic ISSN: 1863-9941
DOI
https://doi.org/10.1007/s00068-018-0962-3

Other articles of this Issue 3/2018

European Journal of Trauma and Emergency Surgery 3/2018 Go to the issue

Original Article

The anatomical relationship of the neurovascular structures in direct posterior lateral gastrocnemius split approach for posterolateral tibial plateau fractures

Original Article

Reduced invasive and muscle-sparing operative approaches to the posterolateral chest wall provide an excellent accessibility for the operative stabilization!

Review Article

Long-term follow-up of 1217 consecutive short-stem total hip arthroplasty (THA): a retrospective single-center experience

Review Article

The source of cell-free mitochondrial DNA in trauma and potential therapeutic strategies

Letter to the Editor

Reply to the letter to the editor “Minimized approaches to the posterolateral chest wall in the fixation of rib fracture” by Yih-Wen Tarng, Yi-Pin Chou, Tung-Ho Wu, Hsing-Lin Lin

Original Article

Pediatric out-of-hospital cardiopulmonary resuscitation by helicopter emergency medical service, does it has added value compared to regular emergency medical service?